CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2017 BMT Tandem Meetings
Oncology Conference Multimedia
View more videos >>
Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant
Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma
Dr. Scott on Conditioning Regimens for Stem Cell Transplants
Oncology Conference Articles
Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma
Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.
Prophylactic Letermovir Limits CMV Infections Post-Transplantation
Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.
Vorinostat Lowers Acute GVHD in Patients Receiving Unrelated Donor HSCT
Vorinostat combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant.
Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy
Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.
New and Emerging Approaches Target the Immunologic Chaos of GVHD
A host of new and emerging therapies for acute and chronic graft-versus-host disease are on the horizon and include B-cell depletion, IL-2, inhibitors of JAK1/JAK2, extracorporeal photopheresis, and the BTK inhibitor ibrutinib.
Novel Pretransplant Conditioning Regimens Seek to Reduce Relapse in Blood Cancers
Sergio A. Giralt, MD, reviewed emerging strategies to improve stem cell transplantation outcomes by reducing the risk of relapse using novel drugs and targeted radiotherapy.
Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant
Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.
Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT
Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.
Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma
According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.
CPX-351 Offers Potential Bridge to Transplant for Secondary AML
More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.
NDA Withdrawn in Melanoma, Promising Phase III Results in Breast Cancer and Ovarian Cancer, and More
FDA Approves Niraparib for Ovarian Cancer
Expert Discusses QoL Benefits of Active Surveillance for Low-Risk Prostate Cancer
Efforts Continue to Introduce Immunotherapy Into Earlier NSCLC Settings
Expert Tackles Efficacy of PD-L1 Testing for NSCLC in 2017
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.